A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women.

Trial Profile

A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Opicapone (Primary) ; Moxifloxacin
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2015 Results (QT/QTc evaluation) presented at the 1st Congress of the European Academy of Neurology.
    • 18 Jun 2015 Results: at clinical and supra-therapeutic doses, opicapone was not associated with QTc prolongation, presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 17 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top